We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 137.20
Bid: 136.80
Ask: 137.60
Change: 0.60 (0.44%)
Spread: 0.80 (0.585%)
Open: 141.80
High: 141.80
Low: 135.40
Prev. Close: 136.60
ELM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Response to open letter from Franklin Templeton

20 Sep 2023 12:09

RNS Number : 0945N
Elementis PLC
20 September 2023
 

London, 20 September 2023

Elementis plc

Response to open letter from Franklin Templeton

The Board of Elementis plc (the "Company" or "Elementis") notes the open letter from Franklin Mutual Advisers ("Franklin"), published today, in which Franklin requests the Board to initiate an immediate sale of the Company.

The Board engages with and welcomes feedback from all shareholders and is focused on delivering value for stakeholders.

The Board has held a series of discussions with Franklin to understand their view and consider their request. After careful consideration, with the support of its advisors, the Board does not consider an immediate sale of the Company to be in the best interests of its shareholders and is issuing this announcement to clarify its response.

The Board agrees with Franklin's comments on Elementis' attractive assets

The Board notes and agrees with Franklin's comments about Elementis' attractive assets. In particular, the comments about our healthy market positions, strong gross margins that demonstrate the premium nature of our products and potential for upside in a cyclical recovery alongside substantial operational improvement initiatives.

Pure specialty chemicals business on track to achieve full potential

Following the successful divestment of the Chromium business which completed in January 2023, Elementis is a pure play specialty chemicals business focused on adding value by making our customers' formulations look, feel, and perform better. Elementis is now a higher growth, higher margin, less cyclical and less carbon intensive business.

This focus on advantaged, high value products will enable us to deliver higher quality earnings and margins, with lower volatility, and generate significant shareholder value.

We continue to make progress towards our medium-term goal of 17% adjusted operating margin. As a cash generative business, combined with the sale of our Chromium business, we continue to make progress towards our target of below 1.5x net debt / EBITDA.

Interim results demonstrate resilient performance alongside ongoing execution of the strategy

In our 2023 interims we delivered resilient results in challenging macro-economic conditions that have seen many other specialty chemicals companies downgrade expectations for 2023. Alongside this resilient performance Elementis continues to execute against its strategy which is built around the three pillars of Innovation, Growth and Efficiency.

Board focus on driving value for shareholders

The Board regularly views the Company's strategic alternatives with its financial advisors. Our Board does not believe that Franklin's request to initiate an immediate sale of the Company is currently in the best interests of its shareholders given the substantial value still be to be realised.

We look forward to updating shareholders on our strategic progress, including the next wave of growth and efficiency initiatives, at our upcoming Capital Markets Day on 14 November 2023.

 

Enquiries

Elementis plc

Paul Waterman, Chief Executive Officer

Ralph Hewins, Chief Financial Officer

Eva Hatfield, Head of Investor Relations Tel: +44 7553 340 380

 

 

Teneo

Martin Robinson Tel: +44 (0) 20 7353 4200

Olivia Peters Email: elementis@teneo.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RSPLMMBTMTMTBRJ
Date   Source Headline
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review
1st Sep 20239:42 amRNSTotal Voting Rights
1st Aug 20239:44 amRNSTotal Voting Rights
27th Jul 20232:16 pmRNSHolding(s) in Company
27th Jul 20237:00 amRNSHalf-year Report
20th Jul 202312:58 pmRNSHolding(s) in Company
3rd Jul 202310:21 amRNSTotal Voting Rights
29th Jun 20234:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20239:32 amRNSDirector/PDMR Shareholding
30th May 20238:06 amRNSDirector Declaration
2nd May 20239:37 amRNSTotal Voting Rights
26th Apr 20232:12 pmRNSResult of AGM
26th Apr 20237:00 amRNSAGM Trading Statement
17th Apr 202310:15 amRNSDirector/PDMR Shareholding
17th Apr 202310:10 amRNSDirector/PDMR Shareholding
13th Apr 20234:24 pmRNSDirector/PDMR Shareholding
3rd Apr 202311:28 amRNSDirector Declaration
3rd Apr 20239:34 amRNSTotal Voting Rights
24th Mar 20239:27 amRNSDirector/PDMR Shareholding
22nd Mar 20234:02 pmRNSAnnual Financial Report & Notice of AGM
17th Mar 20232:58 pmRNSAdditional Listing
14th Mar 20237:30 amRNSDirector Declaration
9th Mar 20232:50 pmRNSDirector/PDMR Shareholding
9th Mar 20232:47 pmRNSDirector/PDMR Shareholding
7th Mar 20237:00 amRNSPreliminary results year ended 31 December 2022
1st Mar 20239:53 amRNSBlock listing Interim Review
1st Mar 20239:39 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.